Ebola Outbreak

• An outbreak of the Bundibugyo virus, a rare strain of Ebola, has been detected in the Ituri province of the Democratic Republic of the Congo. • The first patient developed symptoms in late April and died in Bunia, with further clusters of unexplained illnesses reported in early May near the gold-mining area of Mongbwalu. • This specific strain is particularly dangerous because there are currently no approved vaccines or antibody treatments, forcing patients to rely on basic supportive care.

• The Democratic Republic of the Congo is facing its deadliest Ebola outbreak in history, with the death toll now exceeding 2,300 people. • Official data reveals a total of 4,945 recorded cases and 2,325 deaths, marking a significant escalation in the disease's impact. • This surge is critical as it represents the highest mortality rate ever recorded for an Ebola outbreak within the Central African nation.

• NanoViricides, Inc. (NYSE American: NNVC) announced on August 18, 2026, that it will soon begin a Phase II clinical trial for NV-387 oral gummies. • The trial aims to treat the Bundibugyo Ebola virus during what is described as the largest and most rapidly expanding outbreak to date in the Democratic Republic of Congo. • This development is critical as the company seeks to provide an accessible, antiviral treatment that prevents viral escape during a major public health crisis.

• NanoViricides has received regulatory approval to launch a Phase II clinical trial for NV-387 oral gummies to treat Ebola in the Democratic Republic of Congo. • The trial aims to combat the current outbreak, which is described as the largest and most expanding in the region's history. • Led by Professor Katoto and supported by experts like Fogarty Fellow Patrick, the study leverages specialized implementation research networks to scale novel treatments.

At least 2,325 people have been killed, according to government data, surpassing the death toll from 2018-20 outbreakThe Ebola outbreak in the Democratic Republic of Congo is now the deadliest in the country’s history with at least 2,325 people killed, according to government data, surpassing the toll from the 2018-20 outbreak.Congo’s public health institute said on Sunday that confirmed cases had risen to 4,945, including 101 new cases detected in the previous 24 hours. Continue reading...

Man dies in Bas-Uele after travelling from Haut-Uele, as head of WHO says outbreak on track to be deadliest everThe Ebola outbreak in the Democratic Republic of the Congo has spread to a sixth province, officials have said, a day after the head of the World Health Organization said the outbreak was on track to surpass the deadliest in history, which erupted more than a decade ago and killed more than 11,000 people.Jean Kaseya, the director general of Africa CDC, said a death had been recorded in the previously unaffected Bas-Uele province. Kaseya said the man had travelled from Isiro, in Haut-Uele province, to Buta, the capital of Bas-Uele, where he died. Continue reading...

• The WHO chief warns that the current Ebola outbreak in the east of DR Congo, declared on 15 May, is on track to be the deadliest ever. • The virus has already caused over 2,000 deaths, with thousands more cases reported and no approved vaccines or therapeutic drugs available for this specific strain. • Regional instability is severely hindering containment efforts, leaving health workers able to reach only about 30% of affected cases.

• NanoViricides, Inc. (NYSE American: NNVC) received regulatory approval on August 10, 2026, to launch a Phase II clinical trial for its NV-387 oral gummies. • The trial will take place in the Democratic Republic of Congo to treat patients affected by the current largest and most rapidly expanding Ebola outbreak. • This development is critical as the company aims to provide an accessible, antiviral treatment designed to prevent viral escape during a public health crisis.

• NanoViricides has received regulatory approval to launch a Phase II clinical trial for NV-387 oral gummies, designed as a treatment for the Ebola virus. • The trial will take place in the Democratic Republic of Congo to combat the largest and most rapidly expanding Ebola outbreak on record. • The urgency for the treatment is heightened by the virus spreading into displacement camps housing over 4.4 million people, where poor sanitation and medical resources increase risk.

• Health Canada has authorized Moderna to begin a clinical trial for an mRNA vaccine targeting the Bundibugyo strain of the Ebola virus. • The trial aims to combat a significant and ongoing outbreak of the virus currently surging throughout the Democratic Republic of the Congo. • This authorization is critical as it leverages mRNA technology to provide a rapid response to a deadly pathogen in a region facing a public health crisis.